|
East and Central African Journal of Surgery
Association of Surgeons of East Africa and College of Surgeons of East Central and Southern Africa
ISSN: 1024-297X EISSN: 2073-9990
Vol. 13, Num. 1, 2008, pp. 37-40
|
East and Central African Journal of Surgery, Vol. 13, No. 1, March-April 2008, pp. 37-40
The
Prevalence Overexpression Of C-Erbb-2 Oncoprotein In Carcinoma Of The Prostate-
Mulago Hospital
R.
Alenyo1, M. Odida2, S Watya1.
1Department of Surgery, 2Department of Pathology,
Makerere University, Kampala –
Uganda.
Correpondence to:Dr.
Rose Alenyo, Email: Rose Alenyo
,
Code Number: js08007
Background: Over expression of C-erbB-2 a Human epidermal growth factor has
been reported in several human carcinomas including prostate cancer. In
prostate cancer studies have for it to have a prognostic role and to predict
likelihood of resistance in hormonal therapy. The oncoprotein receptors are now
being looked at as possibility of prognostic predictor at the same time as a
target for therapy in cancers.
Objective: To determine the prevalence of over expression of C-erbB-2
oncoprotein receptor using Immunohistochemistry in Mulago Hospital.
Material and Methods: Biopsy samples were taken from
patients suspected to have prostate cancer convectional histology (Hand E)
done. The tumours in the Confirmed slides were then graded as well
differentiated, moderately differentiated and poorly differentiated.
Immunohistochemistry staining was done using avidin-biotin method. To
standardize the staining, the manufacturer (DAKO) supplied both positive and
negative control. A well defined scoring system based upon the number of
C-erbB-2 on the cell surface was applied. The score ranges from score 0 to +3,
over expression is defined as score equal or greater than +2.
Results: over expression was
seen in 18 out of 40 cases. Stastistically there was no association between
histological grades and over expression. But most of the patients that over
expressed C-erbB-2 were either moderately differentiated or poorly
differentiate 14 of the 18 positive cases.
Conclusion and Recommendation: Immunohistochemistry which is
cheap and easy to use can be used in our setting to analyse the level of
C-erbB-2.
Its important
that long term follow up of the patients with over expression is needed to
further ascertain if this outcome is deemed significant.
Introduction
C-erbB-2
Oncoprotein is a
185-KDa glycoprotein, often simply called C-erbB-2oncoprotein receptor. The
C-erbB-2 oncoprotein is encoded by the human epidermal growth factor receptor
-2 (HER-2 orC-erbB-2) proto-oncogene C-erbB-2 is one of the best studied factor
receptor systems.The erbB or type 1-tyrosine kinase factor family
compromises of four homologous epidermal growth factor receptors: erbB-2,
erbB-3 and erbB-4.1 The erbB family plays an important role in regulating cell
growth, survival and differentiation in a complex manner. The erbB-2 is the
preferred heterodimerisation partner within the family and can be stabilised
and transactivated in heterodimers by ligands for the partner erbB monomer,
such as erbB-1or erbB-2 and erbB-4.2 This heterodimerisation between erbB-2 and
other receptor of the family allows for its participation in signal
transduction even in the absence of a cognate ligand. Infarct erbB-2 tends to
show particularly high signalling potency which may explain its significant
role in oncogenic phenotype3,4.
In vitro animal
studies have indicated that the erbB-2 gene amplification and oncoprotein over
expression play a pivotal role in oncogenic transformation, tumorigenesis and
metastasis.5 The normal epithelial cell possess two copies of C-erbB-2 gene and
expresses low level of C-erbB-2 oncoprotein receptors on the cell surface this
is equivalent to some tens of thousands of receptors per cell. With oncogenic
transformation C-erbB-2 gene amplification generates more than the normal gene
copies leading to 10-100 fold increase in erbB-2 monomers on the cell surface
on the cell surface6. The expression of the C-erbB-2 oncogene and
presence of the epidermal growth factor are becoming increasingly important as
prognostic parameters in addition to standard histological and clinical
evaluation of patients with carcinomas. Over expression of the C-erbB-2
oncogene products has been identified in adenocarcinomas of breast, ovaries,
colon, and lung and it’s linked to poor prognosis in a subset of patients with
cancer of the breast and correlates with shorter survivor but not with disease
free intervals7.
C-erbB-2
and prostate cancer: Oncoprotein amplification
are frequently found in solid tumours and often associated with aggressive
growth. This combined with the recent advance in the early detection of prostate
cancer has stimulated the interest in the development of techniques for
determining metastatic potential and prognostic factors. The over expression of
C-erbB-2 is present in 70%to 80% of prostate cancer patients8.
Koeppen et al9 in a retrospective survey of C-erbB-2 over expression in solid tumours by
standardised immunohistochemical assay, found over expression of C-erbB-2
oncoprotein in 15 of 61(24.6%) of prostate cancer cases. The prognostic role
of C-erbB-2 oncoprotein has been noted in many studies. Visakorpi at el al10. found variable immunoreactivity in prostate cancer tissues. The patients with
over expression had locally more advanced disease, higher histological grade,
and a worse 10-year survival than those with C-erbB-2 negative carcinomas. The
tumours with C-erbB-2positivily had two to three times higher S-phase fractions
suggesting that C-erbB-2over expression confers proliferative advantage, by
including secondary changes which are responsible for the acquisition of
tumorigenic and metastatic prostate tissue. Sadasivan et al11 using
a monoclonal antibody and IHC method, nine out of 25 case of adenocarcinomas
showed over expression on flow cytometric analysis corrected with higher
histological grade, higher stage of disease and higher phase and aneuploidy,
suggesting C-erbB-2 to be a prognostic marker.
Kuhn et al12 in a prospective study with 53patients with carcinoma of the prostate using IHC
found definite positive staining in 18 of 53 (34%) cases of prostate cancer.
There was significant association between C-erbB-2 oncoprotein status and
histological grades with(P=0.03). On following the patients for three years he
found positive staining as the disease progressed in those who were previously
negative.
A retrospective
study using paraffin embedded specimens on 124 localised prostate cancer
patients who had no involvement of seminal vesicle or lymph node was done by
Veltri et al patients were divided as a progressors and non-progressors using
PSA level as an indication of recurrence (mean follow up of =8.6+/- 1.8 years).
The status of C-erbB-2 was significant in detecting progression (P=0.0015)13.
Meanwhile Morote
et al14 using Immunohistochemistry, studied over expression of
C-erbB-2 in primary prostatic tissues of 70 patients with metastatic disease.
Positive staining was present in 64.3%. No signicant relation was observed
between histological grade and C-erbB-2 over expression or severity of the
disease based on extent of metastasis. But the average specific survival in
patients with C-erbB-2 over expression was less than in those withC-erbB-2
negativity with (P=0.034).from the results they suggested that over expression
of C-erbB-2 oncoprotein would be considered as an independent prognostic factor
of metastatic prostate cancer14.
Development of
androgen therapy resistant prostate cancer in many patients, for who
therapeutic options remains limited, has led researchers to focus attention on
understanding the molecular genetics of prostate cancer. Such analysis may lead
to identification of relevant new prognostic and therapeutic indicators. The
recent demonstration that a monoclonal anti C_erbB-2 anti bodies (Herceptine)
used in combination with chemotherapy is effective as first line treatment for
women who have C-erbB-2 positive metastatic breast cancer. This has prompted
investigators to evaluate combination of chemotherapy and Herceptine in hormone
refractory prostate cancer15. The aim of this study was to determine
the status of C-erbB-2 oncoprotein among patients with carcinoma of the
prostate attending Mulago Hospital using Immunohistochemistry.
Materials and Methods
The
avidin-biotin methods were used to stain for C-erbB-2. Sections were treated
with antigen retrieval solution PH 6.1 (51700) in micro over for 10 minutes to
improve antigenicity. The primary antibody was rabbit polyclonal antibodies
(DAKO A485) at diluting of 1:20. The primary antibodies was incubated at 370C
for one hour and subsequent incubations were done at room temperature After
gentle washes with three changes of TBS, the sections were incubated with goat
anti-rabbit polyclonal antibodies as secondary antibody at diluting of 1:200
for 30minutes. Sections were washed again in TBS and then incubated with
subsliate chromogen solution for 2-8minutes.
IHC scoring was
based on DAKO Hercep test score, the score ranges from 0 to 3+.
Scores equal or
greater than 2+ was considered as over expression of C-erbB-2 oncoprotein.
Score O, negative; No staining is observed or membrane staining is observed
in less than 10%of tumour cell.
Score 1+, negative; Afaint or barely perceptible membrane staining is
observed in more than 10%of the tumour cells. The cells are only stained in
part of their membrane.
Score 2+weak positive; weak to moderate complete membrane staining is
observed in More than 10% of
tumour cells.
Score 3+strong positive; strong complete membrane staining is observed in
more than 10% of the tumour cells.
Results
Histological
appraisal of the slides was done 50% of the patients had poorly differentiated
carcinoma and only 20% of this had over expression of C-erbB-2 oncoprotein
receptors. The age of the patients ranged from 50 to 86 years. Close to half of
the patients 45% showed over expression of C-erbB-2 oncoprotein receptors
Majority of the patients that had over expression had higher histology grades.
Data is summarized in the table below
Table 1. C-erbB-2Status distribution by Histological grade of prostate
cancer
|
C-erbB-2 status |
Histology |
|
Negative |
Positive |
Well
differentiated |
16(80) |
4(20%) |
Moderate
differentiated |
3(38.4%) |
10(61.5%) |
Poorly
differentiated |
3(42.9%) |
4(57.1%) |
Total |
22(55%) |
18(45%) |
X2 =4.41 Df =2
P = 0.110
No statistical
significance was observed in the relation between histological grades and
C-erbB-2 oncoprotein over expression.
Discussion
Its generally
agreed documented that higher histological grades is associated with over
expression of C-erbB-2 oncoprotein further studies showed an association with
poor prognosis. The frequency of over expression has been shown to vary from
0-100% some of this has been attributed to difference in the material,
reagents, and scoring system. This trend could be aided by development of
certified reference materials for common IHC stains, development of reference
methods, validation of commercial staining instruments and test systems.
In this study
the results are in accordance with those of Kuhn12 who studied 53
cases positive staining was in 6 out of 27(22%) well differentiated carcinoma,
8 out of 20(40%) moderately differentiated carcinoma, and 4 of 6(66%) of poorly
differentiated carcinoma of the prostate (P = 0.03, chi-square test for
trend).16 Although in our study the result was statistically insignificant most
of the patients 14 (77.8%) that were positive for over expression had higher
histological grades Giving an indication that over expression could be
associated with more aggressive disease.
Conclusion and recommendation
Immunohistochemistry
which is cheap and easy to use can be used in our setting to analyse the level
of C-erbB-2. Its important that long term follow up of the patients with over
expression is needed to further ascertain if this outcome is deemed
significant.
Reference
- Riese DJ, Stem DF, Specificity within the
EGF/erbB receptor family signalling net work. Bioessays 20, 41-48
(1998)
- Graus-Porta R Daly JM, Hynes N. erbB-2, the
preferred heterodimerisation patner of al erbB-2 receptors, is a mediator
of lateral signalling EMBO J 16, 1647-1655(1997)
- Karuagaran D, Tzahar E, Beerli R: erbB-2 is a
common auxiliary subunit of EGF,re captor. BOEM J 15,
254-264(1996)
- Tzahar E,Waterman H, Chen X Ahierarchical net
work of intereceptor interactions determines signal transduction by Neu
differeciation factor/neuregulin and epidermal growth factor. Mol cell
Biol,16, 5276-5287 (1996)
- Hynes NE, Stern DF, The biology of erbB-2 and its
role in cancer. Biochim Biophys Ahcta Rev Cancer, 198, 165-185(1994)
- M.J. van de Vijver; Assessment of the need and
appropriate method for testing for the human epidermal growth factor
receptor -2(HER-2) Euro J. cancer37 S11-S17(2000)
- Alina G: Immunoelectron microscopical
identification of the C-erbB-2 oncoprotein in cell carcinoma: acts hi
Pateins with Laryngeal squamu stochem 102,403-411(2000).
- Kim L, and Bruce A.Molecular Biology In: Courtney
M and John Woods (eds), Biological basic of Modern Surgical practise 15 Ed
pp 16-35 London New york. (1997)
- Koeppen H.KW, Wright B.D, Burt A.D, Mcnicol A.M
Overexpression of HER-2/neu in solid tumours: an immunohistochemical
survey: Histopathology 38, 96-104(2001).
- Visakorpi T, Kallioniemi OP, Koivula T,Harvey J,
Isola J. Expression of HER-/2neu oncoprotein in prostatic carcinomas: Mod
Pathal; ( 6):643-8.(1992)
- Sadasivan, R., R.Morgan, S. Jennings, M.
Austenfeld, P. Van Veldhuizen, R.Stephens M. Noble: Overexpression of
HER-2/neu may be an Indicator of Poor Prognosis in prostate Cancer. J
Urol: 150(1): 126-31 (1993)
- Kuhn, E.J.,R.A. Kurnot, I.A. Sesterhenn, E.H.
Chang, and J.W. Moul: Exepression of the CerbB-2 (HER-2/neu) Oncoprotein
in human prostatic Carcinomas. J Urol ;150(5Pt1):1427-33.Bostwick,
(1993).
- Veltri RW, Partin AW, Epstain JE, Marley GM,
Miller CM, singer DS, Patton KP Criley SR, Coffey DS: Quanti tative
nuclear morphometry, markovian texture descriptors and DNA content
captured on a CAS -200 Image analysis system, combined with PCNA and
HER-2/neu Immunohitochemitry for prediction of prostate cancer
progession Vell TriL Biochem Suppl, 19:249-58 (1994).
- Morote, J, 1. De Torres, C. Caceres, C. Vallejo,
S. Schwartz Jr., J. Reventos: Prognostic Value of Immunohistochemical
Expression of the CerbB-2 Oncoprotein in Metastatic Prostate Cancer.Int
J Cancer 20:84(4): 421-5(1999).
- Amanatullah DF , Reuters AT, Zafone BT, Fu M,
Mani S, and pestell RG: Cell cycle dysregulation and the molecular
mechanism of prostate Cancer Front Biosci 1;5: D390 (2000).
© 2008 East and Central African Journal of Surgery
|